Figure 1
![JAK2 is present in both the cytoplasm and the nucleoplasm. (A) Subcellular fractionation was performed in Ba/F3 EPO-R and TF-1 cell lines stably expressing a JAK2V617F EGFP fusion construct and subcellular distribution was assessed by immunoblotting. Endogenous JAK2 and JAK2 GFP Fusion protein were present in both the cytoplasm [C] and the nucleoplasm [N]. α-tubulin was used as a cytoplasmic marker. (B) JAK2 compartmentalizes to both the nuclear and cytoplasmic fractions in fractionation experiments in a panel of leukemic cell lines expressing endogenous JAK2V617F mutation (SET2, UKE1, and HEL).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/26/10.1182_blood-2011-10-385278/4/zh89991183720001.jpeg?Expires=1721111106&Signature=RYcekuOpESmK2fc4GsNYPzjMLbaZ6fgb0tGkw1JBZBufRTqy6AT-gZ3XTkjMwHF-f46olhWx2Ot7B9USKMVuwKzpG4rBvI0qiQC6FJp3u1V8nERcszUkEiNauDCjGOjTuOnCRAq6sbc7dGfYPqN7jsa8N1~bOwB3VhbdmETYId90LjqQPkqVPBgkQ-AxR4zjTdgaYLRCHeDX0jLK4xqBstYqb9wirze1SqsRQZYw0AMgVhJzS7o41RB~s0GVR0LfSRMqqJB3b5ipmCaG81pG8uUN6kbI0aZcc8Pi24anKtoNbaTUlliH8KSYcC2rMQQq9TErGRkC8cEn6GmCS5FgXw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
JAK2 is present in both the cytoplasm and the nucleoplasm. (A) Subcellular fractionation was performed in Ba/F3 EPO-R and TF-1 cell lines stably expressing a JAK2V617F EGFP fusion construct and subcellular distribution was assessed by immunoblotting. Endogenous JAK2 and JAK2 GFP Fusion protein were present in both the cytoplasm [C] and the nucleoplasm [N]. α-tubulin was used as a cytoplasmic marker. (B) JAK2 compartmentalizes to both the nuclear and cytoplasmic fractions in fractionation experiments in a panel of leukemic cell lines expressing endogenous JAK2V617F mutation (SET2, UKE1, and HEL).
